Literature DB >> 23737489

Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.

Mark D Anderson, Ty W Abel, Paul L Moots.   

Abstract

Entities:  

Keywords:  IDH; biopsy; glioma

Mesh：

Substances：

Year:  2013        PMID： 23737489      PMCID： PMC3688023          DOI： 10.1093/neuonc/not063

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.

Authors:  Hayato Ikota; Sumihito Nobusawa; Yuko Tanaka; Hideaki Yokoo; Yoichi Nakazato
Journal:  Brain Tumor Pathol       Date:  2011-01-07       Impact factor: 3.298

2.  Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.

Authors:  David Capper; Felix Sahm; Christian Hartmann; Richard Meyermann; Andreas von Deimling; Jens Schittenhelm
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

Review 3.  Mutant metabolic enzymes are at the origin of gliomas.

Authors:  Hai Yan; Darell D Bigner; Victor Velculescu; D Williams Parsons
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 13.312

Review 4.  Molecular pathogenesis of IDH mutations in gliomas.

Authors:  Koichi Ichimura
Journal:  Brain Tumor Pathol       Date:  2012-03-08       Impact factor: 3.154

5.  IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Authors:  Marta Mellai; Angela Piazzi; Valentina Caldera; Oriana Monzeglio; Paola Cassoni; Guido Valente; Davide Schiffer
Journal:  J Neurooncol       Date:  2011-06-04       Impact factor: 4.506

Review 6.  One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature.

Authors:  Maria Thom; Ahmed Toma; Shu An; Lillian Martinian; George Hadjivassiliou; Bernardo Ratilal; Andrew Dean; Andrew McEvoy; Sanjay M Sisodiya; Sebastian Brandner
Journal:  J Neuropathol Exp Neurol       Date:  2011-10       Impact factor: 3.148

7.  Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.

Authors:  Craig Horbinski; Julia Kofler; Lindsey M Kelly; Geoffrey H Murdoch; Marina N Nikiforova
Journal:  J Neuropathol Exp Neurol       Date:  2009-12       Impact factor: 3.148

8.  Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.

Authors:  Matthew D Cykowski; Richard A Allen; Kar-Ming Fung; Michael A Harmon; Samuel T Dunn
Journal:  Diagn Mol Pathol       Date:  2012-12
  8 in total
  2 in total

1.  Percutaneous CT-guided needle biopsies of musculoskeletal tumors: a 5-year analysis of non-diagnostic biopsies.

Authors:  Connie Y Chang; Ambrose J Huang; Miriam A Bredella; Martin Torriani; Elkan F Halpern; Daniel I Rosenthal; Dempsey S Springfield
Journal:  Skeletal Radiol       Date:  2015-09-04       Impact factor: 2.199

2.  A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis.

Authors:  Bita Geramizadeh; Mahsa Kohandel-Shirazi; Ahmad Soltani
Journal:  Clin Pathol       Date:  2021-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.